According to this Takeda quarterly presentation (https://www.takeda.com/49ac5c/siteassets/system/investors/quarterly-announcements/fy2020/qr2020_q4_p01_en.pdf), Alofisel sales were $7 million USD for the year (Japanese FY ending March21). The Takeda (TiGenix) royalties are single digit on net sales - assuming 5-9% range, this should mean we booked royalties of $350-630k over that year.
Not material as yet but given Alofisel sales were up $105.8% compared to prior year, perhaps the royalty income will quickly catch up to, and potentially surpass that which MSB receives from JCR Pharmaceuticals (≈2-2.5mill/quarter)
According to this Takeda quarterly presentation...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.085(6.09%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $4.505M | 3.127M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 25168 | $1.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 23582 | 7 |
View Market Depth
| Last trade - 13.52pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |